Home › Core › ISCC-IDs › 28C7CoWLfKaas

View ISCC-ID

Core Data

28C7CoWLfKaas
ISCC-ID - digital asset identifier
CCG8jUYV8THxa-CTKu3eehHfavF-CDHAdtT6Go3se-CR584GVernJMF
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

prerequisites for phase i and ii clinical drug trials in human

Ledger Reference

coblo
Source Ledger/Blockchain
12403170
N-th ISCC Decleration on source ledger
2b35eb225d95f14b7d25a6f0a47a2f0a938a6cdaf6b351125a4d4ae0196dd5b5
Hash of block that includes the ISCC-DECLARATION
5624bc993719b7ad82c2f532dc56c45830b807db7f99b6906403c9438ae675ea
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Prerequisites for Phase I and II Clinical Drug Trials in Human", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Michel\u00a0 Bourin", "@type": "Person"}], "license": "cc-by", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://symbiosisonlinepublishing.com/pharmacy-pharmaceuticalsciences/pharmacy-pharmaceuticalsciences37.pdf", "encodingFormat": "application/pdf"}, {"@type": "MediaObject", "contentUrl": "http://pdfs.semanticscholar.org/f736/7dab72774d303b9bc310d42308e5ef447fc8.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Symbiosis Group", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.15226/2374-6866/3/1/00137", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCG8jUYV8THxa-CTKu3eehHfavF-CDHAdtT6Go3se-CR584GVernJMF", "propertyID": "ISCC"}], "datePublished": "2016-06-20"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close